Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with Mycosis Fungoides (MF) or Sézary Syndrome (SS) at Stage IB through Stage IV
• People who have already received at least one standard treatment for their condition
• People who previously had a specific type of full-body radiation therapy (called LD-TSEBT) or a drug called mogamulizumab, as long as their disease did not worsen while on that treatment and they did not stop due to side effects
• People aged 18 or older
• People who are reasonably active and able to carry out daily activities (a doctor would assess this using a standard scale rated 0 to 2)
• People whose side effects from previous cancer treatments have mostly resolved or are very mild by the time they start the trial
• People with MF who have a known history of a skin bacterial infection called staphylococcus, provided they are on a stable dose of preventive antibiotics
• People who have waited the required amount of time since their last treatment before starting the trial (the waiting period varies depending on the treatment — confirm with trial site)
• People whose blood cell counts meet the minimum levels required (confirm with trial site)
• People whose liver function tests are within acceptable ranges (confirm with trial site)
• People whose kidney function meets the minimum level required (confirm with trial site)
• People who have had a previous bone marrow or stem cell transplant from a donor, provided they have no graft-versus-host disease and are not on immune-suppressing medications
• Women who could become pregnant must have a negative pregnancy test before joining
• Women who could become pregnant must agree to use effective contraception during the trial and for 3 months after the last dose
• Male participants and their female partners who could become pregnant must agree to use appropriate contraception during the trial and for 3 months after the last dose

Who may not be able to join:

• People with MF that is at the earliest and most limited stage (Stage IA), or where the disease has spread to the brain or central nervous system
• People currently using corticosteroid medications, with the exception of topical (skin) steroids or low-dose oral prednisone (20 mg per day or less), if that dose has been stable for at least 2 weeks before starting
• People who are pregnant or breastfeeding
• People with an active autoimmune disease, or a history of autoimmune disease that a doctor considers clinically significant
• People who are HIV positive, or who have active hepatitis B or hepatitis C
• People with an active herpes simplex or herpes zoster infection (however, people who have been on herpes prevention medication for at least 30 days before screening, have no active signs of infection, and whose last active infection was more than 6 months ago, may still be considered — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.